deaths (OS)

la/mBC - HER2 positive - 1st Line (L1) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 1st Line (L1)

versus trastuzumab plus chemotherapy
trastuzumab plus endocrine therapy vs. trastuzumab plus chemotherapy 1 certainty unassessable-17%